Bicycle Therapeutics (BCYC) vs Rocket Pharmaceuticals (RCKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rocket Pharmaceuticals (RCKT) has outperformed Bicycle Therapeutics (BCYC) over the past year, losing 22.4% versus a loss of 53.9%. Over five years, RCKT leads with a -90.6% price change compared with -93.6% for BCYC. Rocket Pharmaceuticals is the larger company by market cap ($283.2 million vs $267.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCYC | RCKT |
|---|---|---|
| Share price | $3.82 | $2.58 |
| Market cap | $267.02M | $283.23M |
| 1-day change | +0.13% | -1.90% |
| YTD return | -46.19% | -25.07% |
| 1-year return | -53.87% | -22.42% |
| 5-year return | -93.57% | -90.58% |
| EPS (TTM) | $-2.73 | $-0.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.10 | $5.45 |
| 52-week low | $3.33 | $2.42 |
| Distance from 52-week high | -58.08% | -52.66% |
| Analyst consensus | none | buy |
| Avg. price target upside | +149.02% | +229.44% |
| Average volume | 387.29K | 1.67M |
| Shares outstanding | 50.55M | 109.77M |
| Employees | 288 | 202 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RCKT has outperformed BCYC by 31.5 percentage points over the past year.
About Bicycle Therapeutics
BCYC stock →Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.
Health Care · Biotechnology: Pharmaceutical Preparations · 288 employees
About Rocket Pharmaceuticals
RCKT stock →Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 202 employees
BCYC vs RCKT FAQ
Which is bigger, Bicycle Therapeutics or Rocket Pharmaceuticals?
Rocket Pharmaceuticals (RCKT) is larger, with a market capitalization of $283.23M compared with $267.02M for Bicycle Therapeutics (BCYC).
Which stock has performed better over the past year, BCYC or RCKT?
RCKT returned -22.42% over the past 12 months, compared with -53.87% for BCYC (price return, excluding dividends). Past performance does not predict future results.
Are Bicycle Therapeutics and Rocket Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.